MX2012011666A - Peptidos cluap1 y vacunas que incluyen los mismos. - Google Patents
Peptidos cluap1 y vacunas que incluyen los mismos.Info
- Publication number
- MX2012011666A MX2012011666A MX2012011666A MX2012011666A MX2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- methods
- cluap1
- antigen
- present
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102100033538 Clusterin-associated protein 1 Human genes 0.000 title abstract 3
- 101000945060 Homo sapiens Clusterin-associated protein 1 Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000001939 inductive effect Effects 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen en la presente vacunas de péptido contra el cáncer. En particular también se proporcionan células que presentan el antígeno y CTLs aisladas que dirigen tales péptidos, así como métodos para inducir la célula que presenta el antígeno, o CTL. La presente invención proporciona además composiciones farmacéuticas que contienen como ingrediente activo péptidos derivados de CLUAP1 o polinucleótidos que codifican los péptidos como ingredientes activos. Adicionalmente, la presente invención proporciona métodos para el tratamiento y/o profilaxis (es decir, prevención) de cánceres (tumores), y/o la prevención de recurrencia postoperativa del mismo, así como métodos para inducir CTLs, métodos para inducir inmunidad anti-tumor, usando los péptidos derivados de CLUAP1, polinucleótidos que codifican los péptidos, o células que presentan antígeno que presentan los péptidos, o las composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32209910P | 2010-04-08 | 2010-04-08 | |
| PCT/JP2010/006313 WO2011125139A1 (en) | 2010-04-08 | 2010-10-26 | Cluap1 peptides and vaccines including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012011666A true MX2012011666A (es) | 2012-12-17 |
Family
ID=44762128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011666A MX2012011666A (es) | 2010-04-08 | 2010-10-26 | Peptidos cluap1 y vacunas que incluyen los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JP2013523083A (es) |
| KR (1) | KR20130043632A (es) |
| AU (1) | AU2010350389A1 (es) |
| BR (1) | BR112012025486A2 (es) |
| CA (1) | CA2795423A1 (es) |
| MX (1) | MX2012011666A (es) |
| SG (1) | SG184468A1 (es) |
| TW (1) | TW201134480A (es) |
| WO (1) | WO2011125139A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103951745A (zh) * | 2002-09-12 | 2014-07-30 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| TW201000115A (en) * | 2008-06-11 | 2010-01-01 | Oncotherapy Science Inc | IQGAP3 epitope peptides and vaccines containing the same |
-
2010
- 2010-10-21 TW TW099135910A patent/TW201134480A/zh unknown
- 2010-10-26 BR BR112012025486A patent/BR112012025486A2/pt not_active IP Right Cessation
- 2010-10-26 JP JP2012544968A patent/JP2013523083A/ja active Pending
- 2010-10-26 CA CA2795423A patent/CA2795423A1/en not_active Abandoned
- 2010-10-26 AU AU2010350389A patent/AU2010350389A1/en not_active Abandoned
- 2010-10-26 WO PCT/JP2010/006313 patent/WO2011125139A1/en not_active Ceased
- 2010-10-26 MX MX2012011666A patent/MX2012011666A/es not_active Application Discontinuation
- 2010-10-26 SG SG2012074258A patent/SG184468A1/en unknown
- 2010-10-26 KR KR1020127029304A patent/KR20130043632A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG184468A1 (en) | 2012-11-29 |
| AU2010350389A1 (en) | 2012-10-25 |
| JP2013523083A (ja) | 2013-06-17 |
| CA2795423A1 (en) | 2011-10-13 |
| BR112012025486A2 (pt) | 2017-01-10 |
| WO2011125139A1 (en) | 2011-10-13 |
| TW201134480A (en) | 2011-10-16 |
| KR20130043632A (ko) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| MX2016014711A (es) | Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma). | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| EP3708185A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| EA202091241A3 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| MX366365B (es) | Peptidos de kntc2 y vacunas que los contienen. | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| MX2021001357A (es) | Peptido derivado de cdca1 y vacuna que lo contiene. | |
| EP3590954A3 (en) | Koc1-derived peptide and vaccine including same | |
| PH12016502008A1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml) | |
| BR112013005448A2 (pt) | peptídeos de ttll4 e vacinas contendo os mesmos. | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. | |
| EP3848383A3 (en) | Urlc10-derived peptide and vaccine containing same | |
| EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |